Cardiologist @VCHhealthcare / Clinical Faculty @UBCDoM / Co-Chair @SCC_CCS AF Guidelines / SoME Editor @hrs_journal / Device Committee Chair @CHRS_SCR
Nov 18, 2020 • 6 tweets • 3 min read
@drjohnm I think we gave drugs the best chance possible to succeed.
We undertook aggressive AAD titration over the first 90 days with standardised protocols and a target of AF suppression on continuous loop recorder monitor
- therapeutic achieved doses
- 30% used 2 AADs, 5% used 3 AAD
@drjohnm We had an independent committee review potential crossovers and offer therapeutic suggestions to try and keep people in their assigned group (we had 0 crossovers before a primary endpoint).
We used outcomes beyond « time to first »
Apr 19, 2020 • 45 tweets • 18 min read
Last week I did zoom ECG teaching.
I thought I’d use this thread to share some of the more interesting ECGs I found while prepping.
Here’s the first - May not seem remarkable at first glance but I’ve never seen it before (though I have seen something similar).
Day two of #quarantinECGs.
Not as unique as yesterday but equally dramatic.
I think this ECG is a good example for a multilevel learning environment. Something immediately apparent and something more subtle for the more advanced learner.
Jul 2, 2019 • 40 tweets • 17 min read
1/ In October 2018 the @SCC_CCS released an update to the AF guidelines. This update included a significant revision of the recommendations for anticoagulation therapy around cardioversion. Space limited the discussion so... onlinecjc.ca/retrieve/pii/S…2/ Last month Dr. Mitchell and myself wrote a follow-up article that expanded the evidence review.
In light of that article I thought I'd expand on the previous tweetorial. @CAEP_Docs@UBCDoM@Vadeboncoeur_Al@CANet_nce@BCEmergMedNtwrkonlinecjc.ca/article/S0828-…
Dec 31, 2018 • 30 tweets • 12 min read
1. Earlier in December I had the privilege to speak at the Cardiovascular Collaborative Medicine Conference in Manhattan on the role of catheter ablation post CABANA. I thought I'd present that talk via tweetorial. I'm not sure how well it will adapt to this form, but here goes.. 2. As we work our way through this presentation I want you to keep in mind this patient profile. Specifically we are going to frame the conversation around a young patient with recurrent AF despite the use of AAD therapy as this is the profile where the evidence is most robust.